WO2018008873A1 - Composition cosmétique contenant un polydésoxyribonucléotide (pdrn) - Google Patents

Composition cosmétique contenant un polydésoxyribonucléotide (pdrn) Download PDF

Info

Publication number
WO2018008873A1
WO2018008873A1 PCT/KR2017/006462 KR2017006462W WO2018008873A1 WO 2018008873 A1 WO2018008873 A1 WO 2018008873A1 KR 2017006462 W KR2017006462 W KR 2017006462W WO 2018008873 A1 WO2018008873 A1 WO 2018008873A1
Authority
WO
WIPO (PCT)
Prior art keywords
pdrn
skin
cosmetic composition
weight
present
Prior art date
Application number
PCT/KR2017/006462
Other languages
English (en)
Korean (ko)
Inventor
정춘옥
Tae-seok KIM (김태석)
Original Assignee
주식회사 리온메디코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 리온메디코스 filed Critical 주식회사 리온메디코스
Publication of WO2018008873A1 publication Critical patent/WO2018008873A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising a PDRN (Polydeoxyribonucleotide), and more particularly, cosmetics including PDRN having PDRN, glycathione, and hyaluronic acid as a main component from skin base layer to elasticity, light moisturizing and whitening functions. It relates to a composition.
  • PDRN Polydeoxyribonucleotide
  • PDRN Polydeoxyribonucleotide, hereinafter referred to as 'PDRN'
  • tissue regeneration material PDRN is made of DNA extracted from salmon semen.
  • PDRN is used for the treatment and tissue repair of wounds caused by skin grafts, but it is also used by medical staff to treat some tissue regeneration or inflammation without proper treatment.It also stimulates the A2 receptor, a skin regeneration signal, to secrete various growth factors. It is known as a component that promotes capillary production by VEGF (vascular endothelial cell growth factor), improves blood circulation, anti-inflammatory action and prevents capillary leakage.
  • VEGF vascular endothelial cell growth factor
  • the present inventors focus on tissue regeneration of PDRN, and when using glutathione and hyaluronic acid mixed with PDRN, it can be solved at once from skin base layer to base layer elasticity, light moisturizing and whitening. Succeeded in developing cosmetics containing PDRN that can be used as.
  • An object of the present invention is to provide a cosmetic comprising a PDRN that can be used as a base material mainly composed of PDRN, glutathione and hyaluronic acid, as a lotion or skin application ampoule having elasticity strengthening, light moisturizing and whitening functions, and the like.
  • Cosmetic composition comprising the PDRN of the present invention to achieve the above object is characterized in that it comprises 0.1 to 5% by weight of PDRN in the total composition.
  • the cosmetic composition comprising PDRN is characterized in that it comprises 0.1 to 5% by weight of PDRN, 1 to 7% by weight of glutathione and 5 to 20% by weight of hyaluronic acid in the total weight ratio.
  • the cosmetic composition comprising PDRN is water and PDRN 0.1-5% by weight, glutathione 1-7% by weight, hyaluronic acid 5-20% by weight, butylene glycol 0.5-3% by weight, acetylhexapeptide-6 0.1-1 It is characterized by comprising 0.1% to 0.5% by weight and palmitoylpentapeptide-4.
  • the present invention provides a cosmetic composition
  • PDRN having a skin elasticity, water moisturizing and whitening functions from the base of the skin.
  • the present invention provides a method for producing a cosmetic composition
  • PDRN having a skin elasticity, water moisturizing and whitening functions from the base of the skin.
  • Cosmetic composition comprising the PDRN of the present invention is characterized in that it comprises 0.1 to 5% by weight of PDRN in the total composition.
  • Cosmetic composition comprising the PDRN of the present invention is characterized in that it comprises 0.1 to 5% by weight of PDRN, 1 to 7% by weight of glutathione and 5 to 20% by weight of hyaluronic acid in the total weight ratio.
  • the cosmetic composition comprising the PDRN of the present invention is water and PDRN 0.1 to 5% by weight, glutathione 1 to 7% by weight, hyaluronic acid 5 to 20% by weight, butylene glycol 0.5 to 3% by weight, acetylhexapeptide- 6 to 0.1 to 1% by weight and palmitoylpentapeptide-4 is characterized in that it comprises 0.1 to 0.5% by weight.
  • PDRN polydeoxyribonucleotide
  • the content of PDRN is preferably 0.1 to 5% by weight in the weight ratio of the total composition. If it is less than the above range, the whitening function and skin regeneration function due to the antioxidant of PDRN are not preferable, and if it exceeds the above range, the manufacturing cost It is not preferable to become high.
  • Glutathione reduces the melanin pigment, or the oxidized pigment in the skin, and releases it out of the skin.It maintains 5 mM of the intracellular physiological activity and simultaneously applies glutathione to keep glutathione active. Homeostasis and balance of the skin plays a role in the regeneration of the cells with PDRN as well as skin whitening. Glutathione is an antioxidant that plays an important role in maintaining thiol status and detoxification in the human body. Reduced glutathione (GSH) is known to have a whitening effect
  • the content of glutathione is 1 to 7% by weight in the weight ratio of the entire composition. If it is less than the above range, the whitening function and the skin regeneration function due to the antioxidant are not preferable, and if it exceeds the above range, the manufacturing cost is high, which is preferable. Not.
  • Hyaluronic acid is a complex polysaccharide consisting of amino sugars and uronic acid, which is a major mucopolysaccharide together with chondroitin sulfate, and is widely distributed in all tissues of animals, especially hepatic tissues, and is obtained from umbilical cord or chicken crest. It also prevents the invasion of bacteria and poisons on the skin and has an excellent effect on moisturizing.
  • the content of hyaluronic acid is preferably 5 to 20% by weight in the weight ratio of the total composition. If the content is less than the above range, the skin absorption rate is low, so that the moisturizing function is not preferable, and if it exceeds the above range, the manufacturing cost is high, which is not preferable. .
  • Butylene glycol (Butylene Glycol) is mainly used as a solvent in cosmetics, has little irritation and toxicity to the skin, dissolves the components of the cosmetics and acts as a moisturizer to attract moisture.
  • Acetyl hexapeptide strengthens the skin and strengthens skin elasticity, and increases the amount of collagen or elastin, which is effective in improving wrinkles.
  • Palmitoyl Pentapeptide-4 stimulates the production of collagen and elastin in the dermis and is easy to penetrate the skin due to its low molecular weight. It does not itch or irritate the skin, and it is effective in preventing wrinkles, such as restoring damaged skin against optical damage, and also excellent in preventing skin aging.
  • Water used in the cosmetic composition comprising the PDRN of the present invention is any one of plant extract, fruit extract, plant fermentation or fruit fermentation, including purified water, groin sap, tea extract, green tea extract, bamboo extract, plum extract and the like or One or more mixed solutions may be included.
  • the cosmetic composition including the PDRN of the present invention may be prepared using a lotion or an ampoule for applying a skin and applied to a face or skin, and then may be conveniently used by increasing a absorption rate by attaching a mask pack.
  • the skin lotion prepared by Examples 1 to 3 and Comparative Example of the present invention showed little skin irritation.
  • Moisture retention was tested for the lotion removed by Examples 1-3 and Comparative Examples of the present invention. 10 ml of females in their 20s to 50s were coated with 1 ml / 10 cm 2 of the lotion prepared in Examples 1 to 3 and Comparative Example in a constant temperature and humidity room maintained at 22 ° C. and 50% relative humidity. After 3 hours, the skin moisture content was measured using a skin moisture meter (my-808s, Made in Japan, Scala), and the results are shown in Table 2. Water retention capacity is shown in Table 2 the average value of the water retention measurement of the subjects.
  • the skin whitening effect was tested for the lotion removed by Examples 1 to 3 and Comparative Examples of the present invention.
  • Ten females in their 20s and 50s were attached to an opaque tape with five 1.5 cm diameter holes on their upper arms, and then irradiated with UVB (1.5-2 times the minimum erythema) of each subject.
  • the skin lotion was measured using a color difference meter 4 weeks after applying 2.5 ml of the lotion removed by Examples 1 to 3 and Comparative Example of the present invention every morning and evening.
  • the contrast of the skin is expressed as the 'L' value and shows a value between 0 (black) and 100 (pure white) (Koreans generally have values between 50 and 70).
  • the contrast of the skin is shown in Table 3, the final measurement after application—the initial measurement before application.
  • Example 1 of the present invention Using the lotion prepared in Example 1 of the present invention, a total skin improvement test such as skin elasticity and whitening was performed on two subjects.
  • 2.5 ml of the lotion prepared in Example 1 of the present invention was first applied to the face and the neck, followed by MTS (Microneedle Therapy) procedure, followed by Example 1 of the present invention.
  • 2.5 ml of the lotion prepared by the second application and then the moisture pack to apply for 30 to 40 minutes and then remove.
  • Next day 2.5 ml of the lotion of the first day of the present invention was applied twice a morning and evening to the face and neck, and then gently patted and absorbed twice a week. After 5 procedures, the skin condition was confirmed in FIG. Indicated.
  • Example 1 of the present invention was confirmed that the skin elasticity and moisturizing of the face and neck as a whole, and also confirmed the whitening effect of the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique contenant un polydésoxyribonucléotide (PDRN) et, plus spécifiquement, une composition cosmétique contenant un PDRN qui contient un PDRN, du glutathion et de l'acide hyaluronique en tant que composants principaux et présente ainsi les fonctions de renforcement de la résilience à partir de la couche basale de la peau, production d'une hydratation de rosée et blanchiment. La présente invention comprend de l'eau, 0,1 à 5 % en poids de PDRN, 1 à 7 % en poids de glutathion, 5 à 20 % en poids d'acide hyaluronique, 0,5 à 3 % en poids de butylène glycol, 0,1 à 1 % en poids d'acétyl-hexapeptide-6, et 0,1 à 0,5 % en poids de palmitoyl-pentapeptide-4. La composition cosmétique selon la présente invention peut être commodément utilisée en étant produite sous la forme d'une lotion tonifiante, ou d'une ampoule pour application sur la peau, et en permettant qu'un ensemble de masque soit fixé après l'application de la composition cosmétique sur le visage ou la peau, de façon à augmenter le taux d'absorption. La composition cosmétique présente en outre les effets de renforcement de la résilience à partir de la couche basale de la peau, production d'une hydratation de rosée et blanchiment.
PCT/KR2017/006462 2016-07-06 2017-06-20 Composition cosmétique contenant un polydésoxyribonucléotide (pdrn) WO2018008873A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160085775A KR101722181B1 (ko) 2016-07-06 2016-07-06 PDRN(Polydeoxyribonucleotide)을 포함하는 화장품 조성물
KR10-2016-0085775 2016-07-06

Publications (1)

Publication Number Publication Date
WO2018008873A1 true WO2018008873A1 (fr) 2018-01-11

Family

ID=58500972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/006462 WO2018008873A1 (fr) 2016-07-06 2017-06-20 Composition cosmétique contenant un polydésoxyribonucléotide (pdrn)

Country Status (2)

Country Link
KR (1) KR101722181B1 (fr)
WO (1) WO2018008873A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200057144A (ko) * 2018-11-15 2020-05-26 (주)진우바이오 히알루론산-폴리데옥시리보뉴클레오타이드 복합체와 이를 활용한 필름 및 이의 제조방법
CN112315836A (zh) * 2020-10-30 2021-02-05 润辉生物技术（威海）有限公司 一种高效的外用pdrn的制备方法及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102043739B1 (ko) * 2018-03-30 2019-11-12 (주)웰메이드코엔 인체 지방줄기세포 배양액 추출물과 피디알앤을 함유하는 화장료 조성물
WO2021096089A1 (fr) * 2019-11-15 2021-05-20 주식회사 엑소코바이오 Nouvelle composition comprenant des exosomes dérivés de cellules souches et du polydésoxyribonucléotide en tant que principes actifs
KR102260525B1 (ko) 2019-11-15 2021-06-03 주식회사 엑소코바이오 줄기세포 유래 엑소좀과 폴리데옥시리보뉴클레오티드를 유효성분으로 포함하는 새로운 조성물
KR102346895B1 (ko) 2021-05-28 2022-01-04 주식회사 노아바이오텍 Pdrn추출방법
KR102381273B1 (ko) 2022-01-14 2022-03-30 김동현 콜라겐 합성 촉진 및 모공개선 화장료 및 이의 제조방법
KR20230161776A (ko) 2022-05-19 2023-11-28 주식회사 그라젬 산천어 추출 pdrn을 함유하는 화장품 조성물 및 이를 이용한 화장품
KR102524599B1 (ko) * 2022-10-21 2023-04-21 주식회사 더마룹 비건 pdrn을 함유하여 리포좀화한 탄력, 영양, 재생에 효과적인 조성물
KR102657166B1 (ko) 2024-01-02 2024-04-15 유엔케이코리아 주식회사 Pdrn 및 구리 트리펩티드-1을 유효성분으로 포함하는 주름 감소 및 탄력 개선용 화장료 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2745849A1 (fr) * 2012-12-19 2014-06-25 Idea Medical Devices S.r.l. Composition de polydeoxyribonucleotides et leurs utilisations
WO2015125117A1 (fr) * 2014-02-20 2015-08-27 Mastelli S.R.L. Produit de comblement dermocosmétique et utilisation de celui-ci à des fins esthétiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2745849A1 (fr) * 2012-12-19 2014-06-25 Idea Medical Devices S.r.l. Composition de polydeoxyribonucleotides et leurs utilisations
WO2015125117A1 (fr) * 2014-02-20 2015-08-27 Mastelli S.R.L. Produit de comblement dermocosmétique et utilisation de celui-ci à des fins esthétiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUIZZARDI, STEFANO ET AL.: "Hyaluronate Increases Polynucleotides Effect on Human Cultured Fibroblasts", JOURNAL OF COSMETICS, DERMATOLOGICAL SCIENCES AND APPLICATIONS, vol. 3, 2013, pages 124 - 128, XP055451152 *
MOON, IK JUN ET AL.: "Inhibitory Effects of Polydeoxyribonucleotide on Melanogenesis", PROCEEDINGS OF KOREAN DERMATOLOGICAL ASSOCIATION E-POSTER, vol. 66, no. 2, 2014, pages 272 *
VALDATTA, LUIGI ET AL.: "Evaluation of the Efficacy of Polydeoxyribonucleotides in the Healing Process of Autologous Skin Graft Donor Sites: a Pilot Study", CURRENT MEDICAL RESEARCH AND OPINION, vol. 20, no. 3, 2004, pages 403 - 408, XP008122537 *
YOON, JONG GUK ET AL.: "Wound Healing Effect of Low Molecular PDRN on Experimental Surgical Excision Rat Model", JOURNAL OF THE SOCIETY OF COSMETIC SCIENTISTS OF KOREA, vol. 41, no. 4, 2015, pages 401 - 411, XP055451150 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200057144A (ko) * 2018-11-15 2020-05-26 (주)진우바이오 히알루론산-폴리데옥시리보뉴클레오타이드 복합체와 이를 활용한 필름 및 이의 제조방법
KR102132478B1 (ko) 2018-11-15 2020-07-10 (주)진우바이오 히알루론산-폴리데옥시리보뉴클레오타이드 복합체와 이를 활용한 필름 및 이의 제조방법
CN112315836A (zh) * 2020-10-30 2021-02-05 润辉生物技术（威海）有限公司 一种高效的外用pdrn的制备方法及其应用

Also Published As

Publication number Publication date
KR101722181B1 (ko) 2017-03-31

Similar Documents

Publication Publication Date Title
WO2018008873A1 (fr) Composition cosmétique contenant un polydésoxyribonucléotide (pdrn)
CN106822988B (zh) 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴
US10568938B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2014126310A1 (fr) Composition sol-gel transparente contenant des concentrations élevées de vitamine c et d'un dérivé de vitamine c
EA032439B1 (ru) Композиции и способы для лечения поверхностных ран
CN106420381A (zh) 青蒿素类成分或其组合物在皮肤护理中的新应用
WO2021150027A1 (fr) Formulation de soin de la peau en deux parties
KR102613845B1 (ko) 천연물 유래의 피부개선용 화장조성물
WO2019027132A1 (fr) Composition pour prévention ou traitement des cicatrices
CN115634282A (zh) 贻贝粘蛋白产品治疗和预防黑色素相关疾病中的应用
CN107550753A (zh) 一种具有皮肤修复、抗衰老功能的组合物及其制备方法
CN108653129B (zh) 一种包含天然植物抗敏组合物的皮肤敷料
WO2017011983A1 (fr) Protéine de moule à action adhésive indiquée pour la protection cutanée et de l'appendice cutané
CN105749333B (zh) 一种透明质酸医用敷料及其制备方法
Burd Evaluating the use of hydrogel sheet dressings in comprehensive burn wound care
WO2017030388A9 (fr) Composition pour le traitement de lésions cutanées
WO2015163589A1 (fr) Composition cosmétique contenant mentha haplocalyx comme ingrédient actif
Guyuron et al. Medical-grade tattooing to camouflage depigmented scars
CN104983495A (zh) 一种正压硅凝胶弹力祛疤带及制备方法
WO2020055135A2 (fr) Composition pour le traitement d'une plaie ou d'une cicatrice, comprenant un patch d'hydrogel
JP2021014450A (ja) タトゥーの色を維持し、強化する方法
CN111012944A (zh) 一种基于藻酸盐和透明质酸的液体敷料及其制备方法
CN111714681A (zh) 一种医用贴敷料及其制备方法
CN114569629A (zh) 一种祛疤和皮肤修复的组合物及其制备方法
CN112316108B (zh) 促进及治疗慢性伤口愈合的组合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17824429

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13.05.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17824429

Country of ref document: EP

Kind code of ref document: A1